Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- BioNTech SE (NASDAQ:BNTX) has dosed the first patient in its Phase 2 trial evaluating the BNT111 cancer vaccine.
- The study evaluates the therapeutic cancer vaccine candidate BNT111 in combination with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) - Sanofi SA's (NASDAQ:SNY) Libtayo (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III-IV melanoma.
- BNT111 is the lead product candidate from BioNTech's FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens.
- The trial will enroll around 120 patients and evaluate the effects of the combination and single agents alone.
- The primary endpoint is the overall response rate. Secondary endpoints include overall response rate in the single-agent arms, duration of response, and safety.
- Price Action: BNTX shares are down by 0.56% at $213 during the premarket trading session on the last check Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!